2024-04-27 09:00:00 ET
Summary
- The market remains pessimistic about INMD's prospects, as observed in the stock's decline by -21.6% over the past three months, well underperforming the wider market at +4.7%.
- Part of the headwinds are attributed to the management's lowered FY2024 revenue guidance, building upon the FY2023 slowdown, as borrowing costs are still elevated for prospective buyers.
- Then again, we believe that consumer demand for skin-tightening devices and body contouring products may remain robust, thanks to the popularity of GLP-1 obesity therapies.
- The same has been observed in INMD's growing consumable sales, with it likely to drive intermediate-term growth as equipment sales temporarily stall.
- However, with the stock recording elevated short interest and the market experiencing an uncertain pullback, it may be more prudent to wait for a floor to materialize first.
We previously covered InMode (NASDAQ: INMD ) in January 2024, discussing why we maintained our Buy rating despite the massive plunge over the past three months....
Read the full article on Seeking Alpha
For further details see:
InMode: More Headwinds Than Expected, Wait For A Floor To Materialize (Rating Downgrade)